Comparative Pharmacology
Head-to-head clinical analysis: ISOTRETINOIN versus TEGISON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOTRETINOIN versus TEGISON.
ISOTRETINOIN vs TEGISON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reduces sebum production, inhibits sebaceous gland activity, and induces apoptosis in sebocytes. Binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs) to regulate gene expression.
Retinoid that binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription involved in cell differentiation, proliferation, and apoptosis. It reduces epidermal proliferation and promotes normal keratinization.
0.5-1 mg/kg/day orally in two divided doses for 15-20 weeks; cumulative dose 120-150 mg/kg.
Initial dose: 0.5-1 mg/kg/day orally, divided twice daily; maintenance dose: 0.3-0.5 mg/kg/day. Maximum dose: 1.5 mg/kg/day.
None Documented
None Documented
Clinical Note
moderateIsotretinoin + Estrone sulfate
"The therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Estramustine
"The therapeutic efficacy of Estramustine can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Dienogest
"The therapeutic efficacy of Dienogest can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Medroxyprogesterone acetate
Terminal elimination half-life is approximately 20 hours (range 10-30 hours) for the parent drug. Clinical significance: steady-state achieved in ~5 days with repeated dosing; prolongation in renal impairment is minimal.
Terminal elimination half-life is approximately 120-168 hours (5-7 days) due to extensive tissue storage; clinical effects persist for weeks after discontinuation.
Primarily hepatic metabolism; metabolites excreted in urine (65-80%) and feces (15-35%). Less than 1% excreted unchanged in urine.
Primarily renal (60-80% as metabolites) and biliary/fecal (15-25% as unchanged drug and metabolites).
Category D/X
Category C
Retinoid
Retinoid
"The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Isotretinoin."